The ASX has popped off after Nvidia shrugged off the doubters. Tech and resources stocks are in form, although DroneShield and Magellan are copping another rough day.
With its European and Chinese partners, Kiwi drug minnow AFT Pharmaceuticals plans a 1000-patient trial of a novel iron deficiency therapy.
Independent testing has confirmed the Very High Density technology of Green Critical Minerals is a leader in thermal management.
ReNerve raises $3.2 million from new and existing, and institutional and sophisticated investors.
American Uranium has begun hydrological testing at its Lo Herma ISR uranium project, aiming to assess aquifer performance and well efficiency.
